These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1448961)

  • 21. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
    Burnouf T; Michalski C; Goudemand M; Huart JJ
    Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Photometric determination of total protein in lipemic sera.
    Chromy V; Fischer J
    Clin Chem; 1977; 23(4):754-6. PubMed ID: 844174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative testing of methods of protein concentration determination.
    Varga J; Kálóczy J; Molnár IU
    Ann Immunol Hung; 1975; 18():237-47. PubMed ID: 1235953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of five quantitative methods for determination of total proteins in urine.
    Lizana J; Brito M; Davis MR
    Clin Biochem; 1977 Apr; 10(2):89-93. PubMed ID: 862182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group.
    Poon MC; Aledort LM; Anderle K; Kunschak M; Morfini M
    Transfusion; 1995 Apr; 35(4):319-23. PubMed ID: 7701550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards.
    Gray E; Pickering W; Hockley J; Rigsby P; Weinstein M; Terao E; Buchheit KH
    Pharmeuropa Bio; 2008 Dec; 2008(1):19-30. PubMed ID: 19220978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
    Limentani SA; Gowell KP; Deitcher SR
    Thromb Haemost; 1995 Apr; 73(4):584-91. PubMed ID: 7495063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of serum proteins in the presence of dextran by means of the biuret reaction.
    Gregor A; Kostrzewska E; Godorowska W
    Infusionsther Klin Ernahr; 1977 Feb; 4(1):48-50. PubMed ID: 557456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Technology optimization and properties study of factor IV complex concentrates].
    Zeng R; Yu R; Li X; Wu Y; Qi H
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):142-4. PubMed ID: 15600207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate.
    Goldsmith JC; Kasper CK; Blatt PM; Gomperts ED; Kessler CM; Thompson AR; Herring SW; Novak PL
    Am J Hematol; 1992 Jul; 40(3):210-5. PubMed ID: 1609775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous purification of a clotting factor IX concentrate and continuous regeneration by preparative annular chromatography.
    Iberer G; Schwinn H; Josic D; Jungbauer A; Buchacher A
    J Chromatogr A; 2002 Sep; 972(1):115-29. PubMed ID: 12395951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of biuret and refractometry methods for the serum total proteins measurement in ruminants.
    Katsoulos PD; Athanasiou LV; Karatzia MA; Giadinis N; Karatzias H; Boscos C; Polizopoulou ZS
    Vet Clin Pathol; 2017 Dec; 46(4):620-624. PubMed ID: 28745826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates.
    Burnouf-Radosevich M; Appourchaux P; Huart JJ; Burnouf T
    Vox Sang; 1994; 67(2):132-8. PubMed ID: 7801601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and heat-treatment of factor-IX-concentrates.
    Stampe D; Wieland B; Köhle A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):523-7. PubMed ID: 2465966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of high salt concentrations on color production of the biuret reaction for protein analysis.
    KAWAKAMI T; ROSENTHAL HL
    Am J Clin Pathol; 1956 Oct; 26(10):1169-73. PubMed ID: 13362173
    [No Abstract]   [Full Text] [Related]  

  • 39. [The use of different albumin preparations as calibrators in determining the total protein in blood serum by the biuret method].
    Sigalov AB; Isaeva NV; Bezruchkina SV
    Klin Lab Diagn; 1993; (5):56-8. PubMed ID: 7994548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultrasound-based protein determination in maize seeds.
    Drochioiu G; Ciobanu CI; Bancila S; Ion L; Petre BA; Andries C; Gradinaru RV; Murariu M
    Ultrason Sonochem; 2016 Mar; 29():93-103. PubMed ID: 26584989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.